Marshall Wace
HRTX icon

Marshall Wace’s Heron Therapeutics HRTX Stock Holding History

Marshall Wace’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,308,861
Closed -$1.65M – 3175
2025
Q3 		$1.65M Sell
1,308,861
-1,585,211
-55% -$2.51M ﹤0.01% 1712
2025
Q2 		$5.99M Buy
2,894,072
+1,639,376
+131% +$3.35M 0.01% 1056
2025
Q1 		$2.76M Buy
1,254,696
+237,157
+23% +$460K ﹤0.01% 1328
2024
Q4 		$1.56M Sell
1,017,539
-698,006
-41% -$1.13M ﹤0.01% 1547
2024
Q3 		$3.41M Sell
1,715,545
-45,506
-3% -$109K ﹤0.01% 1149
2024
Q2 		$6.16M Buy
1,761,051
+1,266,697
+256% +$3.89M 0.01% 923
2024
Q1 		$1.37M Buy
+494,354
New +$1.24M ﹤0.01% 1525
2019
Q3 		– Sell
-68,904
Closed -$1.28M – 1782
2019
Q2 		$1.28M Buy
68,904
+68,701
+33,843% +$1.37M 0.01% 872
2019
Q1 		$5K Sell
203
-20,843
-99% -$546K ﹤0.01% 1648
2018
Q4 		$546K Sell
21,046
-8,864
-30% -$244K 0.01% 1069
2018
Q3 		$947K Buy
+29,910
New +$1.11M 0.01% 823
2018
Q2 		– Sell
-12,100
Closed -$334K – 755
2018
Q1 		$334K Buy
+12,100
New +$274K 0.01% 452

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Marshall Wace's HRTX Position: Q4 2025 in Review

Marshall Wace sold out of Heron Therapeutics (HRTX) in Q4 2025, closing a stake of 1,308,861 shares — an estimated $1.65M sold.

Marshall Wace first reported a position in HRTX in Q1 2018 and held it in 12 quarters. The position peaked at $6.16M in Q2 2024. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • Marshall Wace reported no remaining Heron Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Marshall Wace sold 1,308,861 Heron Therapeutics shares in Q4 2025, an estimated $1.65M.
  • Marshall Wace first reported a position in Heron Therapeutics in Q1 2018 and held it in 12 quarters.
  • Marshall Wace's Heron Therapeutics position peaked at $6.16M in Q2 2024.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.